Pathos Revenue, Valuation, Funding & Investors

Anew Labs is a platform developer that builds artificial intelligence systems for identifying pharmaceutical compounds, such as predicting molecular shapes and designing antibodies, by combining computational work with laboratory validation targeting inflammatory diseases.

Lila Sciences is a Boston-based AI platform accelerating discoveries in life sciences, chemistry, and materials. Its tools automate hypothesis generation, experiment design, and data analysis using large language models trained on 100 million publications. Deployed by 50 labs at universities like MIT, it integrates robotic labs for high-throughput synthesis.

Afiniti is a global AI provider deploying patented pairing algorithms to match contact center agents with customers for optimal interactions. The platform enhances outcomes in healthcare, telecom, travel, hospitality, insurance, and banking sectors by analyzing behavioral data. Used by enterprises handling billions of calls annually, Afiniti improves resolution rates, sales conversions, and satisfaction scores through real-time optimization.

ASAPP is an artificial-intelligence company that builds an AI-native customer experience platform for contact centers, covering automation, real-time voice transcription, speech analytics, and live-agent coaching for both agent-assisted and agentless interactions. The platform is designed to help enterprises such as JetBlue and DISH Network cut costs and improve digital engagement across the roughly $400 billion contact-center industry. ASAPP operates from offices in New York, Silicon Valley, Buenos Aires, London, and Bozeman.

Axiom Math AI is a startup developing AI systems for mathematical reasoning and self-improving superintelligence. The San Francisco-based company trains models on vast datasets of theorems, proofs, and competition problems from sources like IMO and Putnam exams. Its platform generates step-by-step solutions for algebra, calculus, and geometry while iteratively refining algorithms through reinforcement learning.

Cresta is a Palo Alto-headquartered AI platform coaching contact center agents in real time for sales and customer service interactions. The software analyzes voice calls from platforms like Amazon Connect and provides sentiment-based guidance during conversations with clients such as BT and American Airlines. Cresta processes millions of interactions monthly across North American and European operations.

DataStax is a Santa Clara-headquartered enterprise software company specializing in distributed databases for generative AI applications. Its Astra DB offers serverless vector search, real-time data ingestion, and Kubernetes-native deployment with integrations to LangChain, Apache Cassandra, and NVIDIA AI Enterprise. Founded in 2008, DataStax supports Fortune 500 clients like Netflix, Intuit, and Barclays through Astra Streaming for event-driven architectures and OpsCenter for database management. The platform handles petabyte-scale workloads with built-in security features compliant with GDPR and SOC 2.

WEKA generates AI infrastructure through its cloud and hardware-agnostic data platform at weka.io. The solution powers performance-intensive AI, ML, and GPU workloads on-premises, in clouds, at the edge, and in hybrid environments. Adopted by 11 Fortune 50 companies and research organizations worldwide, it accelerates data pipelines for enterprises.

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.

InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Brise Pharma is a provider of scientific research and technical services in the pharmaceutical sector, focusing on drug development support and laboratory testing.